February 20, 2014

Active at night, sleepy all day - Sleep disturbances in patients with hepatitis C virus infection

Provided by NATAP

Download the PDF here

Article in Press

Journal of Hepatology 2014
Meike Heeren, Faina Sojref, Ramona Schuppner, Hans Worthmann, Henning Pflugrad, Anita B. Tryc, Thomas Pasedag, Karin Weissenborn
Department of Neurology, Hannover Medical School, Hannover, Germany

"The purpose of this study was to characterize the feature and degree of sleep disturbances in HCV-infected patients without relevant liver disease and to clarify the patients' symptoms. Furthermore we were interested to analyze the relationship between sleep disturbances, neuropsychiatric symptoms and health-related quality of life.......In conclusion, our data showed altered sleep quality in a group of patients with HCV infection associated neuropsychiatric symptoms but only mild liver disease.....wrist actigraphy showed sleep disturbances reflected by a higher nocturnal activity and poorer sleep efficiency........Our data indicate that chronic fatigue is associated with bad sleep quality and increased nocturnal activity in HCV-infected patients.....The patients achieved higher scores for depression, fatigue and sleep disturbances and lower quality of life scores than the healthy controls. Actigraphy showed higher nocturnal activity and worse sleepefficiency in the patients, while the 24-h activity level did not differ between groups. Fatigue and quality of life scores correlated with bad sleep quality and daytime sleepiness."

HIV & Sleep

Disturbances......http://www.natap.org/2012/HIV/050412_06.htm

"On the basis of experimental studies it is known that sleep disturbances are associated with alterations of the immune system.......The alteration of cytokine levels both in the periphery as well as in the brain itself could well be involved in the development of sleep disturbances in HCV-infected patients.......In conclusion, our data showed altered sleep quality in a group of patients with HCV infection associated neuropsychiatric symptoms but only mild liver disease.......In summary sleep-wake disturbances are common in cirrhotic patients. The patients suffer from daytime sleepiness and bad sleep quality and some studies showed a phase delay in the sleep patterns of cirrhotic patients. Our patient group with only mild liver disease showed a different feature of sleep disturbances."

------------------------------

ABSTRACT

Background & Aims
More than 50% of patients with chronic hepatitis C with only mild liver disease complain about chronic fatigue, daytime sleepiness and poor sleep quality. The aim of the present study was to characterize and objectify the sleep disturbances in hepatitis C virus-infected patients.

Methods
Twenty-five women who had been infected with hepatitis C virus contaminated anti-D immunoglobulin in 1978/79 and 22 age-matched female healthy controls underwent actigraphy over a period of 5days to measure motor activity and thereby sleep-wake-rhythm and in addition completed questionnaires for depression, health-related quality of life, fatigue and sleep, and a sleep diary. Liver cirrhosis, a history of neurological or psychiatric disease, history of intravenous drug abuse, shift work, or current medication with effect upon the central nervous system were exclusion criteria.

Results
The patients achieved higher scores for depression, fatigue and sleep disturbances and lower quality of life scores than the healthy controls. Actigraphy showed higher nocturnal activity and worse sleep efficiency in the patients, while the 24-h activity level did not differ between groups. Fatigue and quality of life scores correlated with bad sleep quality and daytime sleepiness.

Conclusions
Our data indicate that chronic fatigue is associated with bad sleep quality and increased nocturnal activity in HCV-infected patients suggesting an alteration of sleep architecture behind fatigue in HCV-associated encephalopathy.

Introduction

About 170 million people worldwide suffer from chronic infection with the hepatitis C virus (HCV), the global prevalence is about 2.35%. In 80% acute hepatitis C infection leads to chronic hepatitis whereas between 1 and 20% - dependent on the presence or absence of risk factors such as older age, male sex, alcohol abuse, or diabetes for example - develop liver cirrhosis [1], [2]. An extremely low rate of liver cirrhosis has been observed in the so-called German Anti-D cohort, a group of women who have been infected with HCV contaminated anti-D immunoglobulin in 1978/79 in Eastern Germany. Wiese et al. reported that only 2% of 1980 women who underwent a follow-up examination 25years after the infection showed liver cirrhosis or a pre-cirrhotic stage while 62% "complained of constitutional symptoms such as reduced exertional capacity, weakness and fatigue, abdominal distention, arthralgia, myalgia, or headaches" [2].

Hepatologists are well aware of the extrahepatic manifestations of the HCV-infection and it has been acknowledged recently that the central nervous system is most frequently affected [3].

Symptoms like chronic fatigue, mood disturbances and cognitive dysfunction occur in HCV infected patients with none or only mild liver disease and are accompanied with a reduction of health-related quality of life. The most frequent symptom with more than half of the patients affected is fatigue. Of note, this holds true also in the absence of advanced liver disease or ongoing antiviral therapy with interferon alpha [4]. In detail, chronic HCV infected patients complain about daytime fatigue and poor sleep quality. Up to now these symptoms are not well described in the literature and the pathogenesis is still unclear [5].

The purpose of this study was to characterize the feature and degree of sleep disturbances in HCV-infected patients without relevant liver disease and to clarify the patients' symptoms. Furthermore we were interested to analyze the relationship between sleep disturbances, neuropsychiatric symptoms and health-related quality of life.

Patients and methods

Patients and controls

One-hundred-forty-three members of HCV patient support groups for women who had been infected with HCV-contaminated anti-D immunoglobulin in 1978/79 were contacted in writing and asked if they were interested in taking part in the study. These patients were considered especially suitable to study the effect of HCV-infection upon sleep features and quality because neither co-infection, nor substance abuse or other concomitant disorders could probably bias the results. Eleven patients had moved and their current address was not available, two patients refused to take part in the study. Forty-two women answered our letter and showed interest (Fig. 1).

These 42 women were contacted via phone for a structured interview concerning the exclusion criteria such as liver cirrhosis, a history of neurological or psychiatric disease, history of intravenous drug abuse, shift work, or current medication with effect upon the central nervous system. Thereafter 17 patients had to be excluded from the study because of current therapy with antidepressants (n=10), opioids or benzodiazepine (n=5) or current interferon therapy (n=2) (Fig. 1).

Finally, twenty-five women were included into the study. The time span since infection was more than 30years and the genotype of the virus 1b in all patients. Liver cirrhosis or severe fibrosis was excluded by calculation of the APRI (aspartate aminotransferase-to-platelet ratio index) score [6], by ultrasound of the liver and/or by liver biopsy.

22 age-adjusted female control subjects were recruited from the clinic staff as well as family and friends of working group members applying the same exclusion criteria as for the patients. Patients and controls gave their written informed consent.

The study has been performed according to the 1975 Declaration of Helsinki and has been approved by the local ethics committee.

Questionnaires

The patients and controls completed several questionnaires including the Pittsburgh sleep quality index (PSQI) [7], the Epworth sleepiness scale (ESS) [8], the fatigue impact scale (FIS) [9], the Beck depression inventory (BDI) [10], the hospital anxiety and depression scale (HADS) [11] and the SF-36 [12]. The PSQI is a subjective measure of sleep quality over the previous 4weeks. The questionnaire consists of 17 items based on components of quality, latency, duration, efficiency, disturbance, use of sleeping medication and daytime dysfunction. The global score varies between 0 and 21. A score 5 can be considered suggestive of significant sleep disturbance. The ESS intends to measure daytime sleepiness. Each item is rated on a 4-point scale. The global score ranges between 0 and 24, with 10 as a cut-off score for pathological daytime sleepiness. The FIS is a self-report scale to measure the impact of fatigue upon patients' daily living activities. It contains 40 items with a scale from 0 to 4. The total score varies between 0 (no fatigue) and 160 (severe fatigue), we choose 50 as a suggested cut-off for pathological fatigue considering own data from healthy controls from former studies. The BDI is a self report scale to measure depression. The questionnaire contains 21 items and a 4-point response scale, ranging from 0 (minimal) to 3 (severe). The global score ranges from 0 to 63, a score 18 can be considered as pathologic. The Hospital Anxiety and Depression Scale (HADS) has been developed for use in in-hospital patients with internal disease to assess emotional alterations. It is a 14 items scale, each scored from 0 to 3. The global range varies between 0 and 21 for anxiety and depression, respectively, with a score 11 indicating anxiety or depression. The Short-Form questionnaire (SF-36) is a survey with 36 questions to measure health-related quality of life (QoL). It provides scores for 8 health domains which can be summarized to a physical and a mental score with a maximum of 400 points for each of the two domains. The cut-off depends on age and sex. The patients' results were evaluated accordingly.

Sleep diary

The patients were requested to fill in a sleep diary to record the "in bed time", time to sleep onset, number of awakenings, "out of bed time", daytime nap, coffee and alcohol consume for the days studied.

Actigraphy

Actigraphy was used to measure motor activity of the subjects throughout a period of 5days. The actigraph is a small device (38mmX37mmX18mm, weight 26g) which is worn on the wrist of the non-dominant hand. We used the accelerometer ActiGraph Monitor GT1M and GT3X (ActiGraph, Pensacola, USA). Both contain a sensor which detects motion with linear piezoelectric accelerometer in a vertical axis [13]. The signal is summarized over epochs of 60s, and given as counts per minute (cpm). Patients and controls were advised to wear the device from Sunday to Saturday 24h per day and to only take it off for washing the dishes or taking a shower. The data stored were downloaded to a computer using the ActiLife 5.0 software. Because of the varying sleep-wake-rhythm during the weekend only data covering the time span from Monday 12pm until Friday 12pm were considered for further analysis.

\e used the floating window algorithm and 20min of consecutive zero counts to identify the non-wear time. Afterwards the data were visually inspected to ensure that information recorded in the sleep diary corresponded with the accelerometer output. The periods of non-wear time as indicated by the participants were excluded from further analysis.

For the sleep scoring we completed the stored data by adding the "in bed time" and "out of bed time" from the sleep diary. The software provides the following parameters:

Sleep onset (the first minute that the algorithm scores "asleep"), total sleep time (the total number of minutes scored as "asleep"), sleep efficiency (number of sleep minutes divided by the total number of minutes the patient was in bed), wake after sleep onset (WASO; the total number of minutes the subject was awake after sleep onset occurred), average awakening (the average length in minutes of all awakening episodes), total counts (total actigraphy counts summed up for the entire sleep period).

The total numbers of epochs stored during the measurement (4X24h) were averaged to measure different categories of activity intensity in a 24h period. We selected 100 counts per minute (cpm) as a cut-point for sedentary behaviour, 100-759cpm for light physical activity, 760-1951cpm for lifestyle physical activity, 1952-5724cpm for moderate physical activity and >5725cpm for vigorous physical activity [14], [15]. In addition we combined the moderate physical activity and vigorous physical activity counts into one class (MVPA >1952cpm) for further analysis as described by Matthews et al. [14]. In addition to the "counts" the data provided bouts of activity. A minimum bout length was 10min, the minimum count level to be considered as bout was 1953cpm and the drop time was 2min [15], [16].

Statistical analysis

Statistical analysis was done using SPSS Version 20. If the data were normally distributed, the results of the questionnaires and actigraphy parameters are summarised as mean values and standard deviations. For not normally distributed data the results are given as median and 25th-75th percentile. A comparison between patients' and control data was performed using the unpaired Student's t test or the Mann-Whitney-U-test accordingly. Spearman correlation was used to look for a relationship between fatigue, QoL and sleep parameters and the actigraphy results because they were not normally distributed. The level of significance was set at a p value of <0.05. In case of multiple comparisons the Bonferroni-Holm correction was applied.

Results

The data of 5 patients and 3 controls had to be excluded from further analysis due to device dysfunction (n=3), insufficient number of monitoring days (n=4) or missing sleep diary (n=1). Thus finally data of 20 patients (age 56.8±4.2) and 19 controls (age 55.3±4.2) were considered for analysis. Six patients had been treated with interferon more than 7years ago. Eight patients were HCV PCR negative, seven spontaneously and one after therapy.

Liver cirrhosis was excluded based on clinical, ultrasound and laboratory data. Liver biopsy has in addition been performed in 3 patients and showed ISHAK 1 fibrosis in 2 and ISHAK 2 fibrosis in one patient. In the other 17 patients liver biopsy was not indicated considering the clinical course as well as ultrasound and laboratory findings. In these patients the APRI score was in median 0.14 (25th-75th percentile: 0.120-0.265).

Five patients are current smokers and 9 patients reported light to moderate alcohol consumption. In the control group 4 women are current smokers and 14 reported light-to-moderate alcohol consumption.

Questionnaires

The results of the questionnaires differed significantly between the HCV-infected patients and the controls, while there was no difference between PCR positive and PCR negative patients (Table 1), or patients with or without alcohol or nicotine consumption. The patients scored higher in the FIS than the controls (p<0.001) showing pathological FIS scores (>50) in 14 (70%). They also showed significantly worse sleep quality. Nineteen of the 20 patients (95%) had a PSQI score indicating sleep disturbances. The patients had also significantly higher ESS scores; 50% showed scores representing pathological daytime sleepiness. Also the depression, anxiety and QoL scores differed significantly between patients and controls (all p<0.05). Thirteen patients (65%) revealed a pathological result in the anxiety subscore and 8 (40%) in the depression subscore of the HADS. Fifty percent of the patients showed pathological results in the BDI (Table 1). The patients had significantly worse quality of life scores compared to the controls (for SF-36 sum-score, physical and mental sub-score p<0.001).

Wrist actigraphy

\he patients showed a significantly higher nocturnal activity than the controls while the time they spent in bed was significantly longer. The time the patients were awake after sleep onset (WASO) and average awakening length at night were also significantly longer. Accordingly they had a worse sleep efficiency than the healthy women (Table 2, Fig. 2).

A subgroup analysis between the PCR positive and negative patients did not show significant group differences except of for the minutes of wake after sleep onset (p=0.036), where the PCR negative patients exceeded the PCR positive ones (Table 2).

For analysis on a daily basis we separated for the activity level. In a 24h period the patients and controls engaged most of the time in sedentary. We could only show that the controls stay a longer time in light physical activity in comparison to the patients. The other activity parameters did not differ significantly between both groups (Table 3). In contrast to the activity level for the night (total counts in entire sleep period, Table 2) the activity level over a whole day (total counts in bouts/24h) was almost the same in the two groups thereby indicating a higher daytime activity in the controls compared to the patients (Table 3).

Using Spearman rank correlation analysis we found a significant relationship in the patient group between the FIS, the PSQI and the ESS respectively (p<0.001). Patients with a higher fatigue score had worse sleep quality and more severe daytime sleepiness. There was no significant correlation between the results of the FIS, the PSQI, the ESS and the actigraphy parameters (Table 4, Table 5). Accordingly the SF 36 results (sum-score, physical and mental score) correlated negatively with the sleep questionnaires (p<0.05) but not with the actigraphy data (Table 4).

Discussion

In the last two decades there has been growing evidence that infection with the hepatitis C virus can lead to brain dysfunction in the absence of severe liver disease [3], [17], [18], [19], [20]. The patients complain about chronic fatigue, cognitive dysfunction, a reduced quality of life and depression. Furthermore they report sleep disturbances such as daytime sleepiness and poor sleep quality [21]. The pathology behind is unclear, as is the interrelationship between these different symptoms.

In the present study we examined 20 women, who had been infected with HCV more than 30years ago but had not developed relevant liver disease, and 19 age-adjusted female healthy controls using a battery of sleep questionnaires and wrist actigraphy.

Like HCV-infected patients in former studies [4], [19], [20] the patients revealed increased scores for depression and anxiety, and decreased QoL scores. Sleep questionnaires indicated a significant alteration of sleep quality, and in accordance with the characteristic complaints wrist actigraphy showed sleep disturbances reflected by a higher nocturnal activity and poorer sleep efficiency.

It must be emphasized that our patients had no significant liver disease, since sleep disturbances are known as a frequent complication of liver cirrhosis. C—rdoba et al. [22] studied 20 patients with liver cirrhosis and 20 healthy controls with a sleep questionnaire and actigraphy for 5 consecutive days. The cirrhotic patients showed a fragmented sleep at night, a higher nocturnal activity and a reduced physical activity over a 24h period compared to the controls. Patients with unsatisfactory sleep showed a shift of activity toward later hours of the day. In 2008 Mostacci et al. [23] studied 178 patients with a diagnosis of non-alcohol-related liver cirrhosis and 178 healthy controls. Patients with cirrhosis showed a significantly higher prevalence of daytime sleepiness and bad sleep quality with difficulties in falling asleep and frequent nocturnal awakenings. Those patients with minimal hepatic encephalopathy had more pronounced daytime sleepiness and night time sleep disturbances in contrast to the other cirrhotic patients. A comparison between the patient groups with pathological and normal blood ammonia level did not show any differences in the parameters of sleep quality and sleep habits. Montagnese and co-workers [24] assessed sleep-wake-disturbances in 87 patients with liver cirrhosis with and without minimal/overt hepatic encephalopathy and 19 healthy controls. They found higher PSQI und ESS scores in the patients compared to the control group. In contrast to the study of Mostacci and co-workers there was no significant correlation between the sleep questionnaires and the presence of hepatic encephalopathy. In concordance to the findings of C—rdoba and co-workers evening type cirrhotic patients took longer to fall asleep and the sleep quality was worse than in patients with earlier sleep timing.

In summary sleep-wake disturbances are common in cirrhotic patients. The patients suffer from daytime sleepiness and bad sleep quality and some studies showed a phase delay in the sleep patterns of cirrhotic patients.

Our patient group with only mild liver disease showed a different feature of sleep disturbances. Although they showed a higher nocturnal activity as well, they had a similar 24h activity level compared to controls and no shift in the sleep-wake-rhythm. Thus the pathogenesis behind is probably different from that in cirrhotic patients with sleep disorder.

Our patient group consists of women who had been infected with hepatitis C virus contaminated anti-D immunoglobulin in the 1970s. Patients with risk factors for developing fatigue (independent of the HCV infection) like intravenous drug abuse and co-infection with the human immunodeficiency virus (HIV) were excluded. Fatigue and depression are known as side effects of interferon therapy in HCV patients [25]. Of note, interferon therapy had been finished at least 7years ago in the 6 patients of our group who had ever been treated. None of the subjects in this study took any medication that could be hold responsible for fatigue and sleep disturbances. However, nearly half of the patients (and 73% of the controls) reported slight to moderate alcohol consumption and 25% had a smoking habit. According to Yamini et al. [26] both factors are associated with the presence of depression, fatigue and sleep disturbances in patients with HCV-infection. They evaluated clinical data of 800 HCV-infected patients for the impact of past and current tobacco use or drinking habits, comorbidities such as diabetes mellitus or hyperlipidemia, history of interferon treatment, fibrosis stage and others upon the presence of depression, fatigue and difficulty sleeping in these patients. The analysis showed a significant relationship between past and present tobacco use and past alcohol use and the presence of depression, between past and present tobacco use and current alcohol use and fatigue, as well as between past and present tobacco use and difficulty sleeping in these patients. In contrast social drinking was associated with a lower risk of difficulty sleeping. Of note, their patient cohort differed significantly from that examined in our study: about half of their patients had a history of drug abuse, one third were heavy drinkers, more than 50% were male and about 50% had advanced fibrosis (28%) or cirrhosis (18%). Depression was present in about 30%, fatigue in 45% and difficulty sleeping in only 3.8%. Considering these differences and the fact that both, smoking and drinking habits of the patients in our cohort were only slight to moderate these factors are unlikely having influenced the results.

Eight of our 20 patients were HCV PCR negative, 7 of them had cleared the virus spontaneously. These HCV PCR negative patients were included into the study and treated as homologous to the HCV PCR positive patients because we have repeatedly shown in previous studies that both, HCV PCR positive and negative patients may develop HCV-infection-associated encephalopathy and present with identical symptoms and findings in brain imaging such as magnetic resonance spectroscopy, Fluor-Desoxy-Glucose positron emission tomography and single photon emission tomography [19], [20], [27]. Accordingly we did not find a significant difference between both patient groups in the present study as well. In the past several studies have shown that the virus replicates in the brain [28], [29], [30], [31]. Different quasispecies of the virus have been detected post-mortem in the liver and the brain of HCV-infected patients. In 2002 Radkowski et al. detected negative strand HCV-RNA, a viral replication intermediary, in autopsy brain tissue of three out of six HCV-infected patients.

As an indication for viral brain compartmentalization in two of these patients viral sequences amplified from the brain differed from those circulating in serum. Based on a sequence analysis of two different viral regions it was suggested that the brain-derived HCV variants were more closely related to the virus present in the lymphoid system than to virus circulating in serum [28]. Forton et al. also described a close relationship between HCV variants present in brain tissue and in lymph nodes [30]. HCV-RNA was also found in the cerebrospinal fluid (CSF) of eight out of 13 patients. Again the sequences of the brain (CSF) derived virus were closer to those found in peripheral blood mononuclear cells (PBMC) than to those circulating in serum of the patients [30], [31]. HCV-RNA positive and negative strands were detected in CD68-positive cells in the brain, which indicates that the cells harboring HCV are macrophages/microglia. It is suggested that HCV-infected macrophages/monocytes enter the brain via the blood-brain-barrier and induce a neuroinflammatory response that might be causative for the development of neuropsychiatric symptoms [29].

We found a significant correlation between the degree of fatigue as represented by the FIS score and the daytime sleepiness and sleep quality (ESS and PSQI). The findings are in line with the results from Carlson et al. [32] who studied 59 hepatitis C patients with different stages of liver disease. They found a significant relationship between the PSQI and FSS (Fatigue Severity Scale) regardless of the stage of liver disease.

We could not find any significant correlations between the results of the fatigue and sleep questionnaires and the actigraphy parameters. In other words the subjective perception of bad sleep quality must not be accompanied with an equivalent amount of nocturnal motor activity. In sleep research actigraphy is a validated tool for activity based sleep-wake monitoring, which was established by The American Sleep Disorders Association [33], [34], [35], [36]. Of note, some patients having difficulties in falling asleep may have the habit lying in bed for a longer period without movement, others move around in bed very often to try to fall asleep. Thus a possible limitation of the validity of actigraphy is detecting wakefulness during a sleep period [33].

\ limitation of our study is the short actigraphy analysis period of 5 out of 7 recorded days. The International Classification of Sleep Disorders (established by the American Academy of Sleep Medicine) requires a minimum of 7days of actigraphy performed in addition to a sleep diary for being able to demonstrate consistency in the pathology of circadian rhythm disorders. Acebo et al. [37] showed that 5 nights of measuring give reliable estimates for evaluating sleep start time, wake minutes and sleep efficiency. Therefore we choose the recording of the five working days of the week for further analysis taking into account that the weekends are usually characterized by alterations of the sleep habits.

The increased HADS and BDI scores and the significant correlation between HADS and BDI scores and ESS and PSQI scores suggest depression as a possible reason for altered sleep quality in our patients. Former studies in patients with depression had shown a relationship between the extent of depression and actigraphy parameters [38]. This could not be observed in our study. While these findings appear inconsistent on the first view they are comprehensible considering the findings of Golden et al. [39] who were able to show that HADS and BDI scores are falsely positive in patients with HCV infection and do not represent the extent of depression.

On the basis of experimental studies it is known that sleep disturbances are associated with alterations of the immune system. Krueger proposed that sleep is a process which is influenced by cytokines, a part of the peripheral and central immune system [40]. Gershon et al. discussed cytokine effects upon the brain as possible mechanism for the development of fatigue in HCV-infected patients [41]. In 2011 de Almeida studied chronic hepatitis C patients to find an association between the degree of sleep quality (provided by the PSQI and FSS) and peripheral blood immunological and virological biomarkers. They detected a different immunological profile in patients with good sleep quality compared to those with bad sleep quality [42]. Wilkinson et al. detected an upregulation of proinflammatory cytokines IL-1, TNF-alpha, IL-12, and IL-18 in post-mortem brain tissue of hepatitis C patients [43]. The alteration of cytokine levels both in the periphery as well as in the brain itself could well be involved in the development of sleep disturbances in HCV-infected patients.

Finally both pathways might play a role in the development of extrahepatic manifestations of chronic hepatitis C virus infection including sleep disturbances: The virus may induce the peripheral immune system which activates proinflammatory cytokines, while the cytokines may alter brain activity by modifying the neurotransmitter systems. Moreover the hepatitis C virus may induce cerebral cytokine production after crossing the blood brain-barrier and thereby alter neurotransmission.

In conclusion, our data showed altered sleep quality in a group of patients with HCV infection associated neuropsychiatric symptoms but only mild liver disease. The extent and the pathogenesis of sleep disorders in patients who had been infected by HCV has to be clarified in further studies considering the cytokine hypothesis as well as recent findings upon altered neurotransmission in HCV-associated encephalopathy [18], [20], [22], [44].

Source

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients

Journal of Hepatology
Volume 60, Issue 3 , Pages 530-537, March 2014

Zobair M. Younossi, Mendel E. Singer, Heshaam M. Mir, Linda Henry, Sharon Hunt

Received 12 August 2013; received in revised form 21 October 2013; accepted 7 November 2013. published online 20 November 2013.

See Focus, pages 471–472

Abstract

Background & Aims
Hepatitis C (HCV) is a common cause of chronic liver disease worldwide. Current standard treatment for genotype-1 patients uses a triple combination of pegylated-interferon alpha (IFN), ribavirin (RBV) and a direct-acting antiviral agent (DAA) with 75–80% sustained virologic response (SVR) rates. The aim is to determine cost-effectiveness of staging-guided vs. treat all HCV genotype-1 patients with interferon-based vs. interferon-free regimens.

Methods
A decision analytic Markov model simulating patients until death compared four strategies for treating HCV genotype-1: Triple therapy (IFN, RBV, DAA) with staging-guidance or treat all, and oral IFN-free regimen with staging-guidance or treat all. Strategies with staging initiated treatment at fibrosis stages F2-F4, with staging repeated every 5years until age 70. The reference case was a treatment-naïve 50-year-old. Analysis was repeated for 50% increase in cost of oral therapy. Effectiveness was measured in quality-adjusted life years (QALYs).

Results
Treatment of all patients with oral IFN-free regimen was the most cost-effective strategy, with an ICER of $15,709/QALY at baseline cost of oral therapy. The ICER remained below $50,000/QALY in sensitivity analyses for baseline and +50% cost of oral therapy scenarios. The treat all strategy was also the most effective strategy; associated with the lowest risk of developing advanced liver disease.

Conclusions
Treating all HCV patients with oral IFN-free regimen reduced the number of patients developing advanced liver disease and increased life expectancy. Additionally, IFN-free regimen without staging may be the most cost-effective approach for treating HCV genotype-1 patients. The efficacy and safety of these regimens must be confirmed using randomized clinical trials.

Abbreviations: HCV, hepatitis C, IFN, pegylated, interferon alpha, RBV, ribavirin, DAA, direct, acting antiviral agent, SVR, sustained virologic response, IFN, BV, DAA, Triple therapy, ICER, incremental cost, effectiveness analysis, QALYs, quality, adjusted life years (a standard metric that incorporates both length and quality of life), CHC, chronic hepatitis C, HIV, immunodeficiency virus, TVR, telaprevir, BOC, boceprevir, GT, genotype, F2 or F4, moderate or advanced fibrosis, F0, F1, mild fibrosis, WAC, wholesale acquisition cost, NADAC, National Average Drug Acquisition Cost, CMS, Centers for Medicare and Medicaid Services

Keywords: Interferon-free oral treatment, Cost-effectiveness analysis, Markov model, HCV, DAA

Source

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

Journal of Hepatology
Volume 60, Issue 3 , Pages 490-499, March 2014

Anna S. Lok, David F. Gardiner, Christophe Hézode, Eric J. Lawitz, Marc Bourlière, Gregory T. Everson, Patrick Marcellin, Maribel Rodriguez-Torres, Stanislas Pol, Lawrence Serfaty, Timothy Eley, Shu-Pang Huang, Jianling Li, Megan Wind-Rotolo, Fei Yu, Fiona McPhee, Dennis M. Grasela, Claudio Pasquinelli

Received 8 August 2013; received in revised form 24 September 2013; accepted 14 October 2013. published online 28 October 2013.

See Focus, pages 471–472

Abstract

Background & Aims

Patients with chronic hepatitis C virus (HCV) infection and prior null response (<2 log HCV RNA decline after greater than or equal to12weeks of PegIFN/RBV) have limited options. We evaluated daclatasvir plus once- or twice-daily asunaprevir in non-cirrhotic genotype 1 null responders.

Methods

In this randomized, phase 2a, open-label, 24-week treatment study, 101 patients received daclatasvir (60mg) once-daily. In addition, 38 genotype 1b patients received asunaprevir (200mg) twice- (DUAL A1) or once-daily (DUAL A2); 36 genotype 1a and 5 genotype 1b patients received asunaprevir twice- (QUAD B1) or once-daily (QUAD B2) plus PegIFN/RBV; and 18 genotype 1a and 4 genotype 1b patients received asunaprevir twice-daily plus ribavirin (TRIPLE B3). The primary endpoint was undetectable HCV RNA 12weeks post-treatment (sustained virologic response, SVR12).

Results

Across all groups, mean HCV RNA was greater than or equal to 6 log IU/ml, and 99% of patients had a non-CC IL28B genotype. SVR12 rates were 78% (A1), 65% (A2), 95% (B1), and 95% (B2). In B3, most genotype 1a patients experienced virologic breakthrough. The most common adverse events were headache, diarrhea, and asthenia. Grade 3–4 aminotransferase elevations were infrequent and not treatment-limiting.

Conclusions

In genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/RBV QUAD therapy is effective for nearly all genotype 1a and 1b patients; but neither DUAL nor TRIPLE therapy is effective for genotype 1a patients. Interferon-free regimens including daclatasvir and twice-daily asunaprevir for genotype 1 null responders should be tailored to subtype.

Abbreviations: HCV, hepatitis C virus, PegIFNα, pegylated interferon alfa-2a, RBV, ribavirin, SVR, sustained virologic response, QUAD,quadruple, DAA, direct-acting antiviral, SVR24, sustained virologic response at 24weeks post-treatment, LLOQ, lower limit of quantification,LOD, limit of detection, SNP, single nucleotide polymorphism, SVR12, sustained virologic response at 12weeks post-treatment, SVR4,sustained virologic response at 4weeks post-treatment, ALT, alanine aminotransferase, AST, aspartate aminotransferase

Keywords: Direct-acting antiviral agents, Sustained virologic response, Hepatitis C treatment, Protease inhibitor, HCV NS5A inhibitor, Non-responders

Source

February 19, 2014

Rutgers scientists identify structure of virus that could lead to hepatitis C vaccine

PUBLIC RELEASE DATE: 19-Feb-2014

Contact: Robin Lally
rlally@ucm.rutgers.edu  
848-932-0557
Rutgers University

Infection is a major global health problem affecting 160 million people worldwide

68830_rel

This is Joseph Marcotrigiano, associate professor of chemistry and chemical biology, Rutgers University. Credit: Nick Romanenko, Rutgers University

Rutgers University scientists have determined the structure of a hepatitis C surface protein, a finding that could assist in the development of a vaccine to halt the spread of the the deadly disease that has infected 3.2 million Americans.

Joseph Marcotrigiano, associate professor of chemistry and chemical biology, says this new research – published online today in Nature – describes an outer region of hepatitis C that enables the virus to evade the body's natural immune system response, causing persistent, chronic infection.

Hepatitis C is constantly mutating, allowing it to infect a host cell and evade the immune responses, causing chronic infection that can be difficult to treat. By identifying the structure of virus's outer protein, Marcotrigiano, the study's lead author, says scientists will be better able to develop a vaccine that targets the immune system to vulnerable regions of the virus in order to prevent infection.

"Viruses are smart and it is a constant battle to keep them out," says Marcotrigiano who collaborated on the research with colleagues from the Center for Advanced Biotechnology and Medicine at Rutgers and Emory University School of Medicine. "That's why the development of a vaccine is so important. It's always better to prevent infection through an effective vaccine then to treat after a chronic infection has been established."

Hepatitis C virus is a major global health problem with 160 million people infected throughout the world, about four times more individuals than those with HIV. Most of those infected do not show symptoms until the virus – the number one cause of liver transplantation – has caused severe liver damage.

The virus is mainly spread through contact with an infected person's blood, such as sharing of needles. Prior to 1992, when donated blood began being tested, the virus was also spread through blood transfusions and organ donation.

Recently, the Food and Drug Administration approved several new drugs that could cure many patients infected with hepatitis C in as little as 12 weeks. However, at about $1000 per pill, this may not be a cost-effective solution to hepatitis C virus.

Developing a vaccine against hepatitis C would not only prevent people from acquiring the disease, Marcotrigiano says, but would also be the most cost-conscious health intervention.

Michael Houghton, a researcher at the University of Alberta in Canada, has been developing a vaccine that is currently being tested clinically. Houghton, who led a team that discovered the hepatitis C virus in 1989, says the Rutgers finding is important because knowing the structure of the virus will help in the development of a vaccine that enables the immune system to produce more infection-fighting antibodies that can neutralize the virus.

Source

University of Westminster develops groundbreaking method to test hepatitis C cure

BIOMEDICAL SCIENCES 17 FEBRUARY 2014

block10

Researchers at the University of Westminster have developed a groundbreaking method which can be used to test a new innovative cure for hepatitis C, a liver disease caused by the hepatitis C virus (HCV).

The cure is the first of its kind ever to be tested in humans and comes in the form of a drug based on gene therapy which is under development by the Australian company Benitec Biopharma.

Around 150 million people worldwide are infected with hepatitis C, and more than 350,000 people die every year from hepatitis C related liver diseases. Hepatitis C is one of the leading causes of liver cirrhosis and cancer, and one of the most common and seriously infectious conditions in the world (according to the World Health Organisation (WHO)).

Although treatments are already available for hepatitis C, these are lengthy, have low chances of success, cause significant side-effects, or the virus is already becoming resistant. The new drug, TT-034, developed by Benitec Biopharma, is based on the biological mechanism for which the Nobel Prize in Physiology or Medicine was awarded in 2006. Unlike anything else currently available to patients, this treatment works with a single injection to directly destroy the hepatitis C virus and remove the infection. The drug is currently undergoing clinical trials in the US with results expected in the coming months.

Dr Sterghios A. Moschos, MSB, Director of Westminster Genomic Services at the University of Westminster, developed the comprehensive and innovative method by adapting state-of-the-art genome sequencing technologies to show exactly how the new drug works. The research was conducted in collaboration with the European Bioinformatics Institute and Benitec Biopharma.

Dr Moschos said: “Our entirely new method to test the new drug has had a major impact on building robust confidence in this innovative therapy. For the first time ever we have shown that there are more ways to hit the hepatitis C infection than previously thought possible, and that this treatment works like a combination of multiple drugs. Our approach has helped Benitec Biopharma, to obtain permission to start clinical trials much earlier than we expected. This is unprecedented for gene therapy, particularly for a disease for which treatments already exist.”

For further information you can read the research paper published on Molecular Therapy Nucleic Acids at nature.com.


About the University of Westminster:

The University of Westminster boasts a vibrant learning environment attracting more than 20,000 students from over 150 nations and we continue to invest in our future with new developments, research projects and new ideas.

We offer highly attractive practice-based courses which are independently rated as excellent, many with international recognition. Our distinguished 175-year history has meant we lead the way in many areas of research, particularly politics, media, art and design, architecture and biomedical sciences, and our position in the city of London allows us to continue to build on our close connections with leading figures and organisations in these areas as well as in the worlds of business, information technology, politics and law.

Our commitment to educating graduates for the needs of professional life attracts high quality students from within the UK and around the globe.

Internationalism, employability and sustainability are key elements in the University of Westminster’s vision for the future and we strive to ensure the very highest standards are met and maintained.

Source

Direct Acting Antiviral Combinations

Provided by NATAP

By Jules Levin, NATAP

.......as you can see the SVR rates will be 96-100%. The lowest SVR rates are in the hardest to treat patients: patients who have both cirrhosis and who are prior non-responders. But I expect we can improve SVR rates in studies in these patients too. Some companies are conducting studies by adding another drug to their regimen, see below last parapgraph/link.

Here is a brief simple table, below the table are links to these studies:
These are results for genotype 1 patients with most but not all the regimens in research studies now. This table does not include Simeprevir+Peg/Rbv which was FDA approved in Dec/13. I included the regimens approved by the FDA for mono and connected in December/13 which are: Sofosbuvir (Sovaldi) + Peg/Rbv, approved for mono & coinfected; Sofosbuvir+Rbv approved for both mono & Coinfected. It is widely believed & the data so far supports this, that HCV/HIV connected will respond the same as mono infected to DAA orals, which is why the FDA gave approval for these aforementioned regimens for coinfection. Gilead & Abbvie have studies ongoing now in coinfection, I think when the FDA does provide the expected approvals later this year both Gilead & Abbvie's regimens I think there will be approvals for coinfection too. BMS is in phase 3 now with daclatasvir+sofosbuvir & expected in Western Europe will be expanded access programs, and studies of this regimen just started, here is link to these studies Daclatasvir+Sofosbuvir-new studies, Daclatasvir Phase 3 IFN-free, EMA Compassionate Use, Accelerated EMA Marketing Review Recommendation

There is no data in coinfection with simprevir+sofosbuvir (COSMOS Study), but it can be considered & the ART interactions with the protease simeprevir must be considered. The same can be said for daclatasvir+sofosbuvir, although the interactions with sofosbuvir & ARTs have been reported at a conference & they are not expected to be clinically significant, there are interactions between ARTs & daclatasvir that also were reported at a conference so they too can be adjusted for.

I did not include in this table Achillion data, Presidio data (NS5A), data from Faldaprevir+Peg/Rbv or the 3 drug DAA oral IFN-free Faldaprevir regimen. As you may know recently development of the non-nuke DAA used in the Faldaprevir 3-DAA study was discontinued which included the Presidio NS5A). I did not include Vertex or Idenix data. Vertex is in phase 2 with VX-135 a nucleotide, same class as sofosbuvir. Idenix is in development of several classes of drugs including a NS5A (same class as Ledipasvir, daclatasvir) & nucleotides. Achillion is in development with a protease, a NS5A and a nucleotide.

Merck is in phase 2 lovely quickly into phase 3. BMS is in phase 3. Roche also presented data recently at AASLD in November/13 but their data was disappointing.

Genotype

Sofosbuvir+Peg/Rbv in HCV/HIV Coinfected (91% SVR) 12 weeks:
Sofosbuvir and Peginterferon Alfa-2a/Ribavirin for Treatment-Naïve Genotype 1-4 HCV-Infected Patients Who Are Coinfected With HIV
http://www.natap.org/2013/IDSA/IDSA_24.htm

Sofosbuvir+Ribavirin in coinfected patients:
AASLD: All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (11/06/13)

This is the most recent data from the COSMOS Study which studied 2 DAAs, sofosbuvir + the protease simeprevir:
AASLD:
SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study - (11/05/13)

Here is the latest study data, slides presented on daclatasvir+sofosbuvir in treatment-naives & in protease failures:
EASL/2012: Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) - (04/19/12)

EASL: Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (04/27/13)

Here is the very recent journal publication of these studies:
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection - (01/17/14)

Here is the latest Abbvie data reported by them of their phase 3 data in a press release just recently:
AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 - (01/31/14)

This is the most recent data reported by Gilead, it is their phase 3 results: GILEAD ANNOUNCES SVR12 RATES FROM THREE PHASE 3 STUDIES EVALUATING A ONCE-DAILY FIXED-DOSE COMBINATION OF SOFOSBUVIR AND LEDIPASVIR FOR GENOTYPE 1 HEPATITIS C PATIENTS - For Immediate Release - (12/18/13)

This is the latest presentation of BMS data for their 3 DAA regimen at AASLD November:
AASLD:
Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection - (11/05/13)

This is the most recent Merck data for their 2-drug DAA combination presented at AASLD in November:
AASLD: High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study - (11/05/13)

Roche
AASLD:
Interferon-free Regimen Containing Setrobuvir in Combination with Ritonavir-boosted Danoprevir and Ribavirin with or without Mericitabine in HCV Genotype 1 Treatment-naive Patients: Interim Results from the ANNAPURNA Study - (11/14/13)

As reported by Jurgen Rockstroh, MD, in his NATAP AASLD report [http://www.natap.org/2013/AASLD/AASLD_109.htm], in the NIAID SYNERGY Trial [http://www.natap.org/2013/AASLD/AASLD_30.htm] 60 HCV mono-infected, treatment naïve, GT-1, patients were consecutively enrolled into 3 arms of a phase 2 clinical trial and received: Arm A - sofosbuvir with ledipasvir (400mg/90mg respectively once daily in a fixed dose combination (FDC)) for 12 weeks, Arm B - FDC + GS-9669 (500mg/day), a non nucleoside NS5B inhibitor for 6 weeks, or Arm C - FDC + GS-9451 (80mg/day), an HCV protease inhibitor for 6 weeks (47). 80-95% of study participants were African-American. In this exploratory trial virological responses were very good with 100% SVR12 in the SOF/LDV (12 weeks arm) (n=20), 90% SVR4 in the SOF/LDV/9669 (6 weeks arm) (n=20) and again 100% SVR4 in the SOF/LDV/9451 (6 weeks arm) (n=20). Only one relapse occurred in the SOF/LDV/9669 arm. Tolerability in all arms was good with no treatment related discontinuation or SAEs. Again this 3 DAA combination study underlines that multiple DAA combinations will work and allow to get rid of interferon as well as ribavirin which is accompanied by greatly improved tolerability. Also the combination of 3 DAAs may allow to shorten treatment duration to 6 weeks at least in easier to treat naïve patient populations which may be very important in the more adherence challenged patient groups.

Source

February 18, 2014

Achieving SVR reduces hep C treatment costs

Provided by Clinical Advisor

Jennifer Southall
February 17, 2014

hepc_0214webexclusives_552080

Achieving SVR reduces hep C treatment costs

Patients with hepatitis C virus genotype-1 infection who had no detectable levels of the virus on blood tests, also known as sustained virological response, experienced a 13-fold reduction in treatment costs vs. those who did not achieve a response five years after treatment, according to researchers.

“We have shown important cost reductions arising from sustained virological response [SVR], which previous studies have either assumed or only observed on small numbers of patients,” William L. Irving, of the University of Nottingham in the United Kingdom and colleagues reported in the Journal of Viral Hepatitis.

For the study, researchers assessed health resource usage and costs associated with treatment outcomes in193 patients who received at least two months of treatment with pegylated interferon and ribavirin therapy for HCV genotype-1 infection.

Unit costs were derived from the National Health Service Payment by Results database and the British National Formulary. Average follow-up was 3.5 years for those who achieved SVR and 4.9 years for non-SVR patients.

There were no patients with SVR that experienced progression of liver disease state. Conversely, 7.4% of patients without SVR progressed from chronic hepatitis to cirrhosis, and 4.9% progressed from cirrhosis to decompensated liver disease.

During the five-year post-treatment observation period, researchers observed a 13-fold increase in costs among patients that failed to achieve SVR. This increased to 56-fold among those who were retreated.

“Achievement of a [SVR] has significant effects on health service usage and costs,” the researchers concluded. “This work provides real-life data for future cost-effectiveness analyses related to the treatment of chronic HCV infection.”

References

  1. Backx M. J Viral Hepat. 2014; 21, 208–215.

Source

HCV Antivirals Race to Market

Provided by Gastroenterology and Endoscopy News
ISSUE: FEBRUARY 2014 | VOLUME: 65:2

by Kate O'Rourke

GEN0214_013a_1946_300

Boston—Over the next five years, a whirlwind of new direct-acting antiviral agents (DAAs) for hepatitis C are expected to get the green light from the FDA. The recent approval of simeprevir (Olysio, Janssen) and sofosbuvir (Sovaldi, Gilead)–containing regimens is only the tip of the iceberg.

“There are multiple, oral, interferon [IFN]-free DAA regimens in late-stage clinical trials with high SVR [sustained virologic response] rates,” said Mark Sulkowski, MD, medical director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology & Hepatology and professor of medicine at the Johns Hopkins School of Medicine, in Baltimore.

These include the Gilead-based regimen of sofosbuvir plus ledipasvir, with or without GS-9669; AbbVie’s ABT450/r plus ABT267 and ABT333; Boehringer Ingelheim’s faldaprevir plus deleobuvir, with or without PPI-668; Janssen’s simeprevir and samatasvir plus TMC647055/r; and Merck’s MK-8742 plus MK-5172. At press time, Bristol-Myers Squibb was in the process of submitting a regulatory filing for either daclatasvir plus asunaprevir, or this combination plus BMS 791325.

Three Mechanisms of Attack

The new hepatitis C virus (HCV) DAAs can be classified into three groups: protease inhibitors, such as simeprevir, with drug names ending in “previr”; polymerase inhibitors, such as sofosbuvir, with names ending in “buvir”; and NS5A inhibitors, such as daclatasvir, with names ending in “asvir.” All of the new agents target specific processes of the HCV life cycle.

Protease inhibitors prevent cleavage of HCV polypeptides into the mature viral proteins necessary for replication and tend to be genotype-specific. Polymerase inhibitors can be subclassified into nucleos(t)ide analogs and non-nucleos(t)ide analogs. Nucleos(t)ide analogs, which are pangenotypic, mimic the natural substrates of polymerase and inhibit the active site. Non-nucleos(t)ide inhibitors, aimed at HCV genotype 1, bind to several discrete sites outside of the polymerase active site, resulting in a conformational change, which in many cases, but not always, leads to loss of polymerase function. The NS5A inhibitors interfere with a membrane-associated phosphoprotein involved in HCV virion production. The treatment strategy involving these new agents is to include drugs that attack at least two different HCV targets in a single regimen.

“We are now going to get into an era of using combinations of direct-acting antivirals,” said Luis Balart, MD, chief of gastroenterology and hepatology at Tulane University School of Medicine, in New Orleans. “There will be two drugs, three in some cases, attacking the virus at different sites. By attacking the virus at two or three different sites, you prevent the resistance to agents that may lead to failure or cause patients to relapse.”

Robust Pipeline

At The Liver Meeting 2013, investigators presented data on numerous promising DAAs.

GEN0214_014a_1946_300

The LONESTAR trial evaluated an oral, fixed-dose combination tablet containing sofosbuvir and ledipasvir (SOF/LDV FDC). In this trial, 60 non-cirrhotic, treatment-naive patients with HCV genotype 1 infection were randomized to receive treatment with either SOF/LDV FDC for eight weeks, SOF/LDV FDC plus ribavirin for eight weeks or SOF/LDV FDC for 12 weeks. Additionally, 40 patients who had not achieved SVR after previous treatment with an HCV protease inhibitor regimen were randomized to receive 12 weeks of treatment with SOF/LDV FDC or SOF/LDV FDC plus ribavirin; 55% of these patients had compensated cirrhosis. Only two patients in the entire study experienced relapse (one patient was lost to follow-up), and the drugs were well tolerated.

The ELECTRON trial examined SOF/LDV FDC in 110 patients with HCV genotype 1 and included five cohorts. Prior null responders with stage F4 fibrosis received SOF/LDV FDC or SOF/LDV FDC plus ribavirin for 12 weeks. Prior null responders with F3/F4 disease received 12 weeks of SOF/LDV FDC plus ribavirin, with or without GS-9669, an NS5B non-nucleoside inhibitor. In the fifth cohort, treatment-naive patients without cirrhosis received SOF/LDV FDC plus ribavirin for six weeks. SVR rates at week 12 were 68% in treatment-naive patients and 70% in treatment-experienced patients with stage F4 fibrosis who received 12 weeks of SOF/LDV FDC. All other patients achieved SVR at week 12.

The National Institute of Allergy and Infectious Diseases SYNERGY trial tested SOF/LDV FDC alone for 12 weeks or in combination with GS-9451 or GS-9669 for six weeks in HCV genotype 1–infected patients; nearly 90% of patients in the trial were black. SVR at week 12 was 100% in patients who received only the fixed-dose tablet. Among patients who received combination treatment, SVR at week 4 was 90% at the time the data were reported, with one relapse. Efficacy was not reduced in patients with baseline NS5A resistance variants, and the regimens were well tolerated.

At press time, Gilead was finalizing regulatory filing for SOF/LDV FDC in HCV genotype 1 patients.

The PEARL-I trial tested 12 weeks of treatment with ABT-450/r, an HCV protease inhibitor dosed with ritonavir, plus ABT-267, an HCV NS5A inhibitor, in HCV genotype 1b, treatment-naive patients (n=42) and prior null responders (n=40) with stage F1 to F3 fibrosis. Roughly 95% of treatment-naive patients and 90% of null responders achieved SVR at week 12. There were no treatment discontinuations due to adverse events, and only one drug interruption because of grade 3 alanine aminotransferase elevation.

Researchers also presented results from a cohort of HCV genotype 1 patients treated in the AVIATOR trial with ABT450/r, ABT267 and ABT333 for 12 or 24 weeks, including 159 treatment-naive patients and 88 null responders. All 24 patients in the trial who required dose reductions achieved SVR at week 24. In the 223 patients who maintained full doses, 92.1% of treatment-naive patients and 94% of null responders achieved SVR at week 24.

The SOUND-C3 trial tested faldaprevir and deleobuvir plus ribavirin for 12 weeks in HCV genotype 1a (n=12) and 1b (n=20) patients. Although 10 of the 12 HCV genotype 1a patients failed therapy, 95% of patients with genotype 1b (19 of 20) achieved SVR at week 12. A Phase III trial in genotype 1b patients is under way.

In another trial of faldaprevir and deleobuvir, 12 weeks of treatment including PPI-668, with or without ribavirin, is being tested in 37 patients with HCV genotype 1a. At press time, all 13 patients who were evaluable at week 4 had achieved SVR. Only one patient discontinued therapy due to gastrointestinal symptoms.

The C-Worthy trial tested the NS5A inhibitor MK-5172 plus two doses of MK-8742, with (n=52) or without (n=13) ribavirin for 12 weeks. SVR rates at week 12 ranged from 89% to 100%. None of the patients discontinued treatment because of side effects. One patient who suffered a virologic relapse had HCV genotype 1a; he had an NS5A polymorphism in Y93N and a protease mutation in D168A/D, both of which were thought to play a role in the treatment failure.

Exciting Results, With Caveats

The list of DAA regimens in development outlined in this article is not even exhaustive. And although clinicians are enthusiastic about the new drugs, they also realize that increased options will bring challenges, especially because there are no clinical trials comparing one new DAA regimen with another. The activity of the new DAAs is being compared to historical data.

“What we are seeing are new Phase III trials that are going to be producing approved drugs that have never been compared with any other regimens,” said David Nelson, MD, vice president for research, University of Florida, Gainesville. “It is fantastic to move those drugs forward, but when we try to understand how those regimens will compare with each other in populations, it will be years before we have that type of data.”

Dr. Nelson pointed out that there are many new regimens for HCV genotype 1 that have similar SVR rates. He believes that most clinicians will make decisions based on data from Phase II and Phase IV studies, the cohort and case–control studies using drugs in special populations.

“We will have a lot of data like that and, of course, we will see a lot of case series and guidelines and opinions, based on a lower level of evidence. The highest standard of evidence will be limited, which will really challenge us to select the best regimen.”

Fred Poordad, MD, vice president of academic and clinical affairs at The Texas Liver Institute, San Antonio, said clinicians will need to scrutinize the drug combinations.

“In general, when you look at an antiviral drug, you need think about its resistance profile, whether it’s pan-genotypic, how potent it is, the adverse-event profile and the drug–drug interaction profile,” Dr. Poordad said.

For many of the new DAAs, clinicians will not be able to rely on traditional baseline predictors of response.

“From AVIATOR, we learned that some of our previously learned baseline predictors do not hold true. Things such as subtype, high viral load, degree of fibrosis excluding cirrhosis and IL28B[interleukin-28 B] status did not seem to affect the efficacy, even in this null-responder population,” Dr. Poordad noted. “I think the good news is that cirrhotics, even cirrhotic nulls, can achieve very high SVR rates with these oral agents. The caveat is the numbers are all small.”

Dr. Nelson agreed: “We, unfortunately, still see very small numbers of cirrhotics in most registration trials, so we need to be careful about extrapolating data on limited patients to broad real-world representation.”

Redefining Treatment Failures

According to Dr. Sulkowski, the new DAAs might change current notions about HCV resistance to these drugs. This concept is supported by a single patient in the LONESTAR trial who was treated for eight weeks with sofosbuvir plus ledipasvir and then relapsed after treatment. At the time of relapse, the patient’s viral quasi-species included variants with mutations conferring decreased susceptibility to both sofosbuvir and ledipasvir. The key features of this patient’s case, Dr. Sulkowski said, were the presence of the S282T mutation, which has been rarely seen in patients treated to date, and what happened next with retreatment: When clinicians initiated a second round of treatment with the same drugs, sofosbuvir and ledipisvir, plus the addition of ribavirin, the patient had robust and rapid viral suppression, and following a longer course of therapy (24 weeks), achieved SVR.

“Clearly, we need to learn more about retreatment of DAA failures, and that is one of our next challenges,” said Dr. Sulkowski. “This single case report may redefine how we think about treatment failures.”

DAAs a Homerun

What will definitely be redefined is the patient experience.

“The difference between these new DAA regimens and IFN and ribavirin is the difference between night and day,” said Dr. Balart. “The side-effect profile is so much better. These patients don’t get the systemic malaise, where they feel like they have the flu every day. We have had patients who have been sick from something else, such as an appendectomy, that had nothing to do with DAAs, and they were able to continue therapy.”

With the side-effect profile and the shortened treatment time, 12 weeks in the majority of studies, the new regimens are a homerun, according to Dr. Balart.

Which combinations ultimately get used in clinical practice will be influenced by which drugs get to market first.

“Whichever drugs are first to market always have an advantage, because physicians become familiar with them first,” Dr. Balart said. “However, given enough time, others will eventually catch up and become part of the available armamentarium, much like what has happened in the HIV treatment arena.”


Dr. Sulkowski has received consulting fees from Abbott, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck & Co. and Vertex Pharmaceuticals. Dr. Balart has received research grant support from AbbVie, Bayer, Boehringer Ingelheim, Genentech, Genfit, GI Dynamics, Gilead, Janssen, Merck, Ocera, Salix Pharmaceuticals and Takeda Pharmaceutical; he has been involved with the advisory boards of AbbVie, Gilead, Janssen and Merck; and he has been on the speakers’ bureaus of Boehringer Ingelheim, Janssen, Merck and Salix. Dr. Poordad is a speaker for Gilead; he has received grant/research support from all of the companies mentioned in this article, except for AbbVie; and he is a consultant for Abbott, Achillion, Anadys, Inhibitex, Merck, Novartis, Pfizer, Pharmasset, Theravance and Tibotec. Dr. Nelson has received grant/research support from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech-Roche, Gilead, Merck and Vertex, and has served on the advisory committee/review panel for AbbVie, Gilead, Merck and Vertex.

Source

Screening urged for Hepatitis C but drug costs are prohibitive

Provided by CMAJ

February 18, 2014

18feb14_newsWide

With new medications that cure over 90% of hepatitis C, experts are urging that screening recommendations expand to include all Canadians born between 1945 and 1975.

Photo Credit: Tetra Images/ThinkStock

Sergeant Lance Gibson contracted hepatitis C from a blood transfusion in 1981, but only received a diagnosis 28 years later.

“My liver was already in stage 5 liver disease,” explains Gibson. “So when I found out, it was already too late and I needed a transplant.”

As is typical of hepatitis C, he had no obvious symptoms of liver disease, which likely contributed to the delay in diagnosis.

With new medications that cure over 90% of hepatitis C, liver disease experts are urging that screening recommendations expand to include all Canadians born between 1945 and 1975. But there are two difficulties with this plan: Who will do all the screening? And who will pay for the new medications when the cost of a cure is $60 000?

The current practice of screening only those at high risk of exposure to hepatitis C, such as intravenous drug users or those exhibiting symptoms of the disease, is outdated, says Dr. Morris Sherman, chairman of the Liver Foundation. “The bigger concern is the far larger group of people who are not injection drug users, or at least not current injection drug users, and who did not acquire their disease recently, but acquired it many years ago.”

Hepatitis C is transmitted by contact with infected blood, including through shared needles or other illicit drug paraphernalia, contaminated sharp instruments, some higher-risk sexual behaviours and blood transfusions or organ transplants prior to 1992 in Canada.

Testing all Canadians born 1945–1975 would capture some 80% of individuals with the disease, Sherman estimates based on an analysis of Public Health Agency of Canada data. According to the agency, about 240 000 Canadians are infected with hepatitis C. The disease is linked to chronic liver disease and increased risk of liver cancer.

With the new medicines approved by Health Canada, hepatitis C is also “one of the very few, maybe the only, chronic viral disease that can be cured by medication,” says Sherman.

The United States has already adopted widespread screening of citizens born 1945–1965. The hope is that earlier diagnosis and treatment will make stories like Gibson’s rare.

However, not everyone is convinced that expanding screening recommendations is the right approach.

Alan Cassels, a drug policy researcher at the University of Victoria in British Columbia is one such critic. “I’ve seen numerous examples in the past of large-scale screening programs launched on populations without any adequate consideration to the downsides or the harms inflicted on the population.”

Cassels also questions whether there are more pecuniary motives behind the push for wider screening.

“We should focus our energy on the high-risk group, but then again, that’s not where the money is,” he says. “You can’t deny the market forces at play when it comes to screening.”

Although Health Canada has approved a medication to cure hepatitis C, provincial governments have yet to decide whether they will fund the drugs. That’s a big problem because the medicines are expensive.

Sovaldi (sofosbuvir), currently under review at the Canadian Agency for Drugs and Technologies in Health prior to potential approval by the provinces for drug formularies, is set at $650 per tablet in Canada. Sherman says that governments or insurance companies who opt to cover the drug will likely pay less. Until then, patients with hepatitis C can expect to pay about $60 000 out of pocket for the cure.

Meanwhile, it remains unclear how current numbers of liver specialists will be able to meet increased demand for screening.

“The short answer is, with difficulty,” says Sherman. “I think hepatologists are maxed out at the moment.” He notes that wait-times vary across the county, but are in the order of three to six months if not longer.

Sherman anticipates family doctors, as well as gastroenterologists and infectious diseases doctors, will play a greater role in the management of hepatitis C to meet the demand created by wider screening.

But Dr. Frank Martino, past president of the Ontario College of Family Physicians, says that family doctors are already stretched thin prioritizing the many messages and updates received from various specialists. When asked how he keeps up, he muses: “That’s the perennial question, isn’t it? Getting education out there is crucial.”

Sherman believes these obstacles can and will be overcome.

“Hepatitis C is an unprecedented situation for health care,” he argues. “I don’t know if there’s ever been a situation where there are so many people who require such expensive drugs that are so effective. And failure to provide these drugs is going to have a major impact on patient survival.”

DOI:10.1503/cmaj.109-4727

— Michael Fralick, CMAJ

Source

Treating HCV -- Is the Price Right?

Gastroenterology

Published: Feb 18, 2014

By Michael Smith, North American Correspondent, MedPage Today

1001604276

New drugs on the horizon hold out the promise of being able to cure up to 90% of people with chronic hepatitis C (HCV). They are also promising to be expensive.

Eyebrows went up recently when Gilead Sciences announced the per-pill price for its new anti-HCV drug sofosbuvir (Sovaldi) would be $1,000. Over a 12-week treatment period, that amounts to $84,000 -- without counting the cost of other medications that would be used with sofosbuvir.

The other recently approved medication -- Janssen's simeprevir (Olysio) -- is being priced at $66,360 for a course of treatment, again without the cost of other medications.

But are those costs out of line for drugs that promise to cure a notoriously refractory illness in eight or nine cases out of 10? Especially when you consider that HCV is widespread, underdiagnosed, and leads in many cases to serious liver disease and death?

Short answer: No one really knows.

"There's a lot of sticker shock in medicine," according to Nancy Reau, MD, of the University of Chicago Medical Center.

But the price tag has to be weighed against the benefit, she and colleague Don Jensen, MD (also at Chicago) argued in a recent article in Hepatology that tried to parse the issue.

In the case of HCV, that's not a simple matter.

The CDC estimates that some three million Americans have chronic HCV, although most don't know it because it is usually without symptoms for many years.

But the disease has some serious consequences -- in the U.S., it is the leading cause of cirrhosis and liver cancer, the most common reason for liver transplantation, and it's estimated that 15,000 people die of HCV-related causes every year.

HCV treatment is measured with what's called the sustained virologic response, or SVR -- no detectable virus 24 weeks after the end of a course of treatment. A person whose treatment results in an SVR has less than a 1% chance of relapse, history shows, and to all intents and purposes is cured.

No Bargains

Cures have never been cheap or easy to come by. The earliest therapy was interferon-alfa for 24 weeks at a cost of less than $20,000 in today's dollars, Reau and Jensen noted.

The downside was that only 6% of patients achieved an SVR -- were cured. "That's an expensive therapy -- to treat 100 people to get six cures," Reau told MedPage Today.

But the odds of achieving SVR steadily improved: first with the use of 48 weeks of pegylated interferon, coupled with ribavirin, and then in 2011 with the addition of the first agents aimed directly at the virus -- the protease inhibitors (PIs) telaprevir and boceprevir.

However those therapies remain expensive and -- in real-world use -- not startlingly effective, according to Andrea Branch, PhD, of Mount Sinai Hospital in New York City.

Branch and her students looked back at 147 patients treated in their hospital with telaprevir, plus peginterferon and ribavirin, and asked how much a cure cost.

Bottom line? The median cost of treatment was $83,509 -- about 65% of that for telaprevir -- but only 44% of patients achieved an SVR, so that the per-cure cost was a whopping $188,859.

If the new drugs live up their promise of SVR rates in the range of 80% to 90%, Branch toldMedPage Today, it may well be that they will be cheaper to use -- on a per-cure basis -- than PI-based triple therapies.

"If these new drugs perform as expected and the costs are as expected, I think there will be an economic saving compared with previous triple therapy," she said.

Following the Numbers

Branch and her group will be monitoring outcomes with the new drugs and hope to have some real-world data in about 9 months, she said.

For an individual HCV patient, a cure can be quite literally priceless, Branch said -- the gift of life. But how do cost and benefit play out across the whole healthcare system?

On a broad scale, the equation is simple, Reau said: "People with hep C cost money."

For instance, one study found that the average annual health care cost for a patient with HCV was $24,176 -- but the expense rose markedly with advanced disease, reaching $59,995 among patients with end-stage liver disease.

"The only way to truly prevent that is to treat people before they declare themselves as someone who is going to get end-stage liver disease," she said.

A liver transplant, for instance, costs about $577,000, all in. A 12-week course of treatment that cured the HCV and prevented the need for transplant would be a good deal -- unless the therapy were horrendously expensive.

Even preventing some of the less serious complications would save money. A 2013 study among HCV patients found that curing them (with peginterferon and ribavirin) reduced annual medical costs by $2,648 on average, compared with patients treated but not cured.

On the other hand, those studies looked at patients already diagnosed with HCV and displaying at least some symptoms. What about the millions of hidden cases? What's the number needed to treat to prevent the serious consequences?

Boomer Disease

The CDC is urging all Americans born from 1945 through 1965 to get tested for HCV, arguing that they could then get treated with the new drugs, which the agency says would save lives and prevent many of the other consequences of the disease.

The cost-benefit implications of treating those people are not known, although Reau said it's likely they resemble the diagnosed cases in at least one way -- about a third will go on to have serious HCV-related disease.

Absent a cure, their HCV will be a drain on the healthcare system for years.

Traditionally, HCV treatment has been aimed at the sicker patients, largely because the therapy itself has had such unpleasant side effects that a relatively healthy person would be better off skipping it.

The downside of that practice has been that sicker people generally do less well on therapy, inflating the cost per cure, Branch said.

Indeed, many physicians have been "warehousing" relatively healthy patients, waiting to treat them until the less toxic direct-acting agents to win approval.

Another aspect of the cost issue is that prices aren't written in stone, Reau said, noting that four pharmaceutical companies have drugs in the pipeline. "It's hard to imagine that when there are four companies out there vying in the hep C space that some of that consumer drive won't affect prices," she said.

The drugs themselves are not expensive to make, according to a study presented at the 2013 meeting of the American Association for the Study of Liver Diseases.

Looking just at the chemistry, researchers led by Andrew Hill, PhD, of Liverpool University in England, estimated that, for example, the full 12-week course of sofosbuvir would cost about $136 to make.

Naturally, drug makers will want to recover the costs associated with the development program and make some money for their shareholders. For instance, among other costs Gilead paid $11.2 billion to buy the company that first created sofosbuvir.

There is pressure for Gilead to charge less for the drug in the developing world, and the company is reportedly in talks with Indian firms to make and market sofosbuvir at a fraction of the U.S. sticker price.

That pressure is likely to be placed on other manufacturers as well and, of course, there will be continuing pressure in the developed world to lower prices.

In the U.S., Reau and Jensen noted, the baby boomer generation is now old enough that much of the HCV treatment costs for that cohort will be borne by Medicare.

Moreover, a recent study in Alabama found that HCV prevalence appears to be higher among the uninsured and those on Medicaid than those with private insurance or Medicare.

In that context, widespread HCV treatment is likely to be "a financial burden on our health care system," but, Reau and Jensen argued, it will higher in the long run if people are not treated.

Source

Also See: Sticker Shock and the Price of New Therapies for Hepatitis C: Is it worth it?

February 17, 2014

Complementary and alternative medications in hepatitis C infection

World J Hepatol. 2014 January 27; 6(1): 9-16.
Published online 2014 January 27. doi: 10.4254/wjh.v6.i1.9.

Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Dina L Halegoua-De Marzio and Jonathan M Fenkel.

Dina L Halegoua-De Marzio, Jonathan M Fenkel, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States
Author contributions: Halegoua-De Marzio DL and Fenkel JM both outlined, researched the topics wrote, and wrote the manuscript.

Correspondence to: Jonathan M Fenkel, MD, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, 132 S. 10th Street, Suite 480, Main Building, Philadelphia, PA 19107, United States. jonathan.fenkel@jefferson.edu

Telephone: +1-215-9558900 Fax: +1-215-5032146

Received October 9, 2013; Revised December 22, 2013; Accepted January 6, 2014;

Abstract

Chronic hepatitis C (CHC) infection affects almost 3% of the global population and can lead to cirrhosis, liver failure, and hepatocellular carcinoma in a significant number of those infected. Until recently, the only treatments available were pegylated interferon and ribavirin, which traditionally were not very effective and have considerable side effects. For this reason, interest in complementary and alternative medications (CAM) in the management of hepatitis C has been investigated. Some CAM has demonstrated therapeutic potential in chronic hepatitis C treatment. Unfortunately, some CAM has been shown to have the potential to cause drug-induced liver injury. This article will review and evaluate many of the natural molecules that interact with the hepatitis C virus (HCV) life cycle and discuss their potential use and safety in HCV therapy, as well as highlight some important interactions between medical and complementary treatments.

Keywords: Hepatitis C infection, Natural molecules, Direct acting antivirals, Hepatotoxicity, Herbal treatments

Core tip: Over the last 10 years there has been a substantial increase in reports of natural compounds displaying anti-viral activity against hepatitis C. At this time, there is no firm evidence supporting complementary and alternative medications for hepatitis C virus infection. Due to a limited number of trials and small numbers of subjects included in them, it is not possible to fully evaluate the risk of adverse events connected with the use of these products.

INTRODUCTION

Hepatitis C virus (HCV) infection affects an estimated 180 million people globally and is a leading cause of chronic hepatitis, cirrhosis, and liver cancer[1,2]. To prevent the complications of chronic hepatitis C (CHC), the goal of therapy is complete viral eradication. For the past decade, a combination of pegylated interferon-α (peg-IFN) and ribavirin was used to treat CHC with disappointing viral eradication rates. These rates were particularly suboptimal in patients with genotype 1 HCV, which is responsible for approximately 60% of worldwide infections[3]. Sustained virological response (SVR) rates for genotype 1 HCV are approximately 40% following 48 wk of peg-IFN/ribavirin and are even lower in patients with HIV co-infection, high baseline viral load, advanced fibrosis, or those of African descent[4-7].

The life cycle of HCV can be divided into three major steps: (1) entry of the virus into its target cells by receptor-mediated endocytosis; (2) cytoplasmic and membrane-associated replication of the RNA genome; and (3) assembly and release of the progeny virions[8]. In recent years, there has been improvement in SVR rates with the development and approval of the first HCV-specific direct-acting antiviral agents (DAAs), namely boceprevir and telaprevir[9,10]. In contrast to the non-specific antiviral activity of peg-IFN and ribavirin, DAA are designed to inhibit viral proteins involved in the HCV life cycle. Still, the first DAAs require coadministration with peg-IFN and ribavirin, and many patients remain intolerant to treatment-associated side effects, including fevers, influenza-like symptoms, headache, cytopenias, fatigue, anorexia, rash, and depressive symptoms.

CAM is being used increasingly across the globe for many chronic diseases[11,12]. The Cochrane Library included nearly 50 systematic reviews of complementary medicine interventions as of 2003[13]. Many people turn to CAM when conventional medicine fails, or they believe strongly in its effectiveness. During the last few years, a substantial increase of reports on natural compounds displaying an anti-HCV activity has been published. There is data that some of these medicinal herbs might have therapeutic potential in CHC, or may alleviate side effects of conventional therapy[13]. CAM use is common among people with CHC. A survey of 1145 participants in the National Institutes of Health (NIH)-supported HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) trial found that 23% of the participants used herbal products[14]. Although sometimes thought by the public to be safer then conventional therapy, there are many reports about liver toxicity and other adverse events from some herbal products[11,15]. The aim of this review is to evaluate the efficacy and safety of treating HCV infection using complementary and alternative medicine.

MEDICINAL HERBAL AND DIETARY SUPPLEMENTS WITH ANTI-HCV ACTIVITY

Silymarin

An extract of the milk thistle plant, silymarin (Silybum marianum), has been used to treat chronic liver disease since the time of the ancient Greeks[16]. Owing to its purported hepatoprotective properties, it is the most commonly used herbal product by individuals with chronic liver disease in the United States[16,17]. A recent publication from the HALT-C study group indicated that 33% of patients with CHC and cirrhosis reported current or past use of silymarin[14]. A follow-up study found silymarin use among CHC patients was associated with reduced progression from fibrosis to cirrhosis, but had no impact on clinical outcomes[16].

The major active component of silymarin, silibinin (a mixture of the two diastereoisomers silybin A and silybin B), is thought to be responsible for silymarin’s hepatoprotective properties[18]. Silymarin appears to inhibit HCV infection at two or more different levels: (1) it inhibits HCV replication in cell culture; and (2) it displays anti-inflammatory and immunomodulatory actions that may contribute to its hepatoprotective effect[19,20]. The inhibition of HCV replication has been attributed to inhibitory action on the NS5B RNA-dependent RNA polymerase.

Clinical studies that have evaluated milk thistle for a variety of liver diseases have yielded inconsistent results and low bioavailability of oral silymarin components[21]. Studies with IV silibinin have shown substantial antiviral effect against HCV in liver transplant recipients, and even in nonresponders with good safety outcomes[22-24]. Although oral administration of silymarin is not effective for the treatment of HCV, intravenous silibinin formulation may represent a future potential therapeutic option.

Green tea extract

Green tea, made from the unfermented leaves of Camellia sinensis, is comprised of several polyphenolic compounds called catechins, and can be concentrated into a green tea extract (GTE). Epigallocatechin-3-gallate (EGCG) is the most abundant and potent catechin contained within GTE, comprising typically approximately 40% of the total polyphenol content[25]. EGCG is a potent inhibitor of HCV entry in primary human hepatocytes independent of the genotype, by blocking virus attachment. This novel inhibitor may provide a new approach to prevent HCV infection, especially in the setting of liver transplantation of chronically infected HCV patients[26,27]. Beyond its antiviral effect on HCV, EGCG may have potential use as a chemopreventative agent for hepatocellular cancer as EGCG may inhibit cancer cell growth. This mechanism of action is thought to be due to tyrosine kinase inhibition and modulation of target gene expression associated with induction of apoptosis and cell cycle arrest in cancer cells[28-34].

GTE is a common ingredient in several dietary supplements, some of which have been withdrawn from the market due to safety concerns. An example of this is Exolise (Arkopharma, France), a weight loss supplement containing high EGCG levels that was withdrawn from the market in April 2003 due to 13 cases of attributable liver injury[35]. Between 1966 and 2008, 216 case reports of toxicity with green tea extracts were identified by the United States Pharmacopeia, of which 34 were concerning for liver toxicity[36]. Recent animal studies with high doses of GTE and EGCG have described dose-dependent hepatotoxicity resulting in severe morbidity and mortality[37]. However, chronic moderate to high dose daily GTE and EGCG use in healthy human volunteers, and selected patients with cirrhosis, was safe and did not impair liver function[38-40]. Although GTE may be very useful in further treatment of CHC and prevention of HCC, its hepatotoxic potential must be acknowledged and monitored carefully in future studies.

Naringenin

HCV associates with β-lipoproteins [very low density lipoprotein (vLDL) and low-density lipoprotein (LDL)] circulating in blood[41]. In addition, HCV replication can be up-regulated by fatty acids and inhibited by statins; this suggests an interaction between HCV, cholesterol, and lipid metabolism[42]. Recent research has found that of HCV secretion is dependent on both apolipoprotein B (ApoB) expression and vLDL assembly in a chromosomally integrated complementary DNA (cDNA) model of HCV secretion[43].

Naringenin is the predominant flavanone present in the grapefruit and is responsible for its bitter taste. Naringenin has been shown to reduce cholesterol levels both in vitro and in vivo[44,45]. Furthermore, naringenin inhibits ApoB secretion by reducing the activity and the expression of the microsomal triglyceride transfer protein (MTP) and the acyl-coenzyme A cholesterol acyltransferase 2 (ACAT)[44,46]. Due to the close link between HCV assembly/secretion and lipoprotein metabolism, there has been extensive study on the impact of naringenin on the secretion of HCV particles[43]. A dose-dependent decrease of core protein, HCV-positive strand RNA, infectious particles, and ApoB has been observed in the supernatant of infected primary hepatocytes in culture after naringenin treatment[43]. Overall, naringenin blocked the assembly of intracellular infectious viral particles without affecting intracellular levels of the viral RNA or protein. Although still at the cell culture phase, naringenin may offer new insight into a promising and novel HCV therapeutic target.

Glycyrrhizin

Glycyrrhizin, a natural compound extracted from the roots of Glycyrrhiza glabra, has been used for more than 20 years as a treatment for chronic hepatitis[47]. It has been used for many centuries in traditional Chinese medicine as an anti-allergic agent. Because of its sweet taste it is also used as a food additive, for example in beverages and licorice[48]. In an attempt to use glycyrrhizin as a treatment for “allergic” hepatitis it was found to lower the transaminases. In a study by Suzuki et al[49] in 1977, plasma transaminases activity improved significantly with glycyrrhizin in patients with chronic liver disease compared to a placebo group.

The mechanism by which glycyrrhizin improves the biochemistry and histology in liver disease is unknown. It is thought to have anti-inflammatory, antioxidant and immunomodulatory activities. Due to this there has been much interest in use of glycyrrhizin in CHC. In the only randomized clinical trial of glycyrrhizin, ALT levels declined modestly during treatment, compared with placebo, but this was not sustained after cessation of treatment and there was no significant effect on HCV RNA levels[50]. In the another trial, statistically significant differences in liver enzyme levels, but not viral loads, between treatment groups were identified during treatment, however, again no sustained response occurred at follow-up[51]. Use of glycyrrhizin is not without side effects. It has been found to cause pseudo-aldosteronism, manifested by sodium retention, hypokalemia and hypertension[52]. Cardiac arrhythmia and acute rhabdomyolysis due to severe hypokalemia caused by excess licorice consumption have also been reported[52-54].

Oxymatrine

Oxymatrine is the major alkaloid extract from the root of sophora flavescens, a deciduous shrub native to China, Japan, South Korea and Russia. It is reported to have antiviral activity against HCV in cell cultures and in animal studies[55-57]. Clinical studies have shown that oxymatrine has some hepatoprotective activity in alcohol toxicity and hepatitis B infection, but not carbon tetrachloride, acetaminophen or cadmium chloride-induced acute hepatitis[58,59]. Oxymatrine is considered to be an antifibrotic, likely through inhibition of lipid peroxidation[60-62]. In a study of HCV-infected subjects randomized subjects to receive either an intramuscular injection of oxymatrine 600 mg/d or other support products such as oral vitamins 47% of the treated cases had complete HCV viral suppression after 3 mo, compared with only 5% in the control group[61]. No serious adverse events were reported. The treated group had significantly more ALT normalizations than the control group in the first 2 mo, but this improvement waned by the end of the third month of treatment. While treatment with oxymatrine holds promise, it is difficult to draw conclusions from the small studies currently available.

Traditional chinese herbal medications

The primary goal of Chinese traditional medicine is to create wholeness and harmony within a person, allowing the mind/body/spirit to heal itself. There have been several randomized clinical trials of traditional Chinese medicine in the treatment of hepatitis C, however, the methodological quality of these studies is generally considered poor[63-70]. In two trials of herbal formulations in combination with interferon-alfa, there was a trend toward greater clearance of HCV RNA and ALT normalization with the combination treatment compared with patients receiving monotherapy[63,64]. In the only placebo-controlled trial of solo therapy with traditional Chinese medicine, a significant reduction in ALT levels during treatment occurred, though no virologic effect was identified[69]. Detailed descriptions of adverse events were not provided for most of these trials. The safety of these medicines is unclear due to the individualized nature of many of the herbal compounds involved, the large number of different herbs in each formulation, and the relatively small number of subjects within each clinical trial.

Vitamin D

The traditional role of Vitamin D (Vit D) was thought to be based upon its interaction in calcium homeostasis, via regulation of intestinal calcium absorption and of bone health. However, over the last several years Vit D has been shown to have a much more complex role in many other host functions, including its interaction with chronic hepatitis C. 25-OH Vit D is made in the liver via cytochrome P450 (CYP27A1) activated hydroxylation of Vit D, brought into the body either by intestinal absorption or endogenous synthesis through sun-exposed skin. It is then converted to 1.25 OH Vit D (calcitriol) in the kidneys, the most active form, where it becomes available to bind to Vit D receptors throughout the body[71,72].

A growing body of clinical evidence has demonstrated an increased prevalence of Vit D deficiency in patients with CHC. As such, Vit D supplementation has been proposed as an adjunct to current standard regimens for treatment of hepatitis C[72]. One study found that mean 25-OH Vit D serum levels were significantly lower in CHC (25 μg/L) than in the controls (43 μg/L)[73]. Importantly, low Vit D has been linked to increased fibrosis and impaired sustained virologic response (SVR) in IFN-based therapy[71]. One clinical trial demonstrated that the addition of Vit D to the standard IFN plus ribavirin treatment significantly increased SVR in patients with genotype 1 CHC[74]. Regarding the underlying molecular mechanisms, an in vitro study showed that Vit D remarkably inhibits HCV production in Huh7.5 hepatoma cells[75]. These cells express Vit D hydroxylases and can eventually generate calcitriol. Notably, treatment with calcitriol resulted in HCV inhibition through induction of IFN-beta. Overall, 25-OH Vit D levels appear to be an important prognostic marker in helping determine the likelihood of SVR. 25-OH Vit D levels should be checked routinely before HCV treatment and supplementation provided to deficient patients, in an effort to enhance treatment response.

Antioxidants

Antioxidants are one of the most common dietary supplements taken by patients with CHC[14]. The use of these supplements is based on the fact that oxidative stress has been attributed to both host inflammatory processes and induction by viral proteins. By increasing antioxidants, one may be able to decrease oxidative stress and therefore decrease liver injury[76]. Existence of oxidative stress in CHC is well documented, as oxidized protein and nucleic acid markers are increased and antioxidant levels are decreased[77-80]. Studies have shown levels of oxidative stress markers to correlate with disease severity, HCV RNA, iron overload, and insulin sensitivity[78,79]. Oxidative stress has also been shown to be an early event in carcinogenesis and is a risk factor for development of HCC in patients with chronic HCV[81].

Multiple trials have shown antioxidants, such as Vitamin E and N-acetyl cysteine, only lead to small reductions in ALT after chronic administration in some instances[82-93]. Further, the decrease in ALT levels in most studies is marginal and is not sustained after stopping the treatment, raising the question of their clinical significance. No study has shown an improvement in outcome. In addition, no study has shown clear benefit of antioxidants as adjuvant to interferon based therapy of HCV. At the doses studied, these antioxidants appear to be well-tolerated, with no specific adverse events reported in any of the trials. However, very large oral doses of N-acetyl cysteine are commonly associated with nausea and vomiting and intravenous administration of N-acetyl cysteine can result in anaphylactoid reactions, which may be more common in patients with chronic liver disease[94]. Therefore, evidence supporting use of antioxidants as useful therapeutic agents in CHC is lacking.

HERBAL SUPPLEMENTS AND DRUG INDUCED LIVER INJURY IN CHRONIC HCV

Drug-related hepatotoxicity is a serious health problem, with broad implications for patients, healthcare providers, the pharmaceutical industry and governmental regulatory agencies. The Drug Induced Liver Injury Network (DILIN), a federally funded consortium of 12 centers in the United States, recently reported the preliminary results of its prospective study[94]. Dietary supplements were implicated in 9% of reported DILI cases. This may be potentially related to increasing use of herbal or dietary supplements in the US population. The importance of these supplements as a cause of DILI is further underscored by a retrospective Japanese study, in which 10% of 879 cases of single agent DILI from 1997 to 2006 were attributed to dietary supplements and 7% to Chinese herbal drugs[95].

In general, chronic liver diseases such as HCV infection are thought to be associated with an increased incidence of hepatotoxicity induced by several specific drugs. Furthermore, patients with underlying liver disease potentially have worse outcomes than healthy individuals if they do develop DILI[96]. For example, the presence of underlying CHC has been shown to increase the risk of DILI caused by the antituberculosis drugs isoniazid and rifampin, as well as ibuprofen and methimazole[15,97,98]. Due to this, patients with chronic hepatitis C should be counseled and screened by physicians on potential risks associated with herbal medications.

DRUG-CAM INTERACTIONS

Another major area of awareness when patients are considering using CAM is whether or not drug-CAM interactions may exist that could impact the medical therapy. This issue is becoming even more complicated with the addition of new medications for the treatment of CHC infection such as simeprevir and sofosbuvir approved for use in the U.S. in December 2013. St. John’s wort (Hypericum perforatum), a common CAM used for the treatment of depression, is an inducer of cytochrome P450 3A4[99]. This cytochrome is also the primary metabolizer of many medications, including the HCV protease inhibitors: telaprevir, boceprevir, and simeprevir. Additionally, St. John’s wort is a potent intestinal P-gp inducer and may lead to a reduced therapeutic effect of the HCV nucleotide polymerase inhibitor sofosbuvir[100]. Concomitant use of St. John’s wort and these HCV treatments is contraindicated and can lead to treatment failure by reducing blood concentrations. Additionally, concomitant use of milk thistle use is contraindicated with simeprevir. This combination may increase levels of simeprevir by milk thistle CYP3A inhibition leading to possible toxicity[101] (Table 1). Garlic extracts, grapefruit juice, and germander also have cytochrome P450 3A4 interactions[102].

Table 1 Herbal supplements to discontinue and/or avoid while taking hepatitis C virus treatment
Herbal Product Effect
Milk thistle (Silybum marianum) Concomitant use of milk thistle may result in increased plasma concentrations of simeprevir
St. John’s wort (Hypericum perforatum) Concomitant use of St. John’s wort may result in decreased plasma concentrations of telaprevir, boceprevir, simeprevir and sofosbuvir

CONCLUSION

Many human studies have shown improvements in subjective symptoms and liver biochemistries in HCV patients with CAM, but there is no convincing data to suggest a definite histological and/or virologic improvement with any of the herbal agents currently available. Vit D seems to have the best available data as adjunctive therapy to antiviral medications in patients with Vit D deficiency. Poorly designed studies, heterogeneous patient populations, lack of standardized preparations, and poorly defined nonobjective end points may partly explain the conflicting reports in the literature.

The safety profiles of the interventions discussed within this review are encouraging at the doses studied. However, the long-term safety for use in the treatment of hepatitis C, either alone or in combination with conventional medicines, has not been established. Comparative and placebo-controlled trials suggest that patients experience no more adverse events with these interventions than with placebo or comparative medications, although short-term clinical trials are not designed to detect rare or delayed adverse events. Physicians need to be cognizant of known or occult use of CAM by their patients because hepatotoxicity and drug interactions may occur with many herbal medications, and may occur more frequently in patients with chronic liver disease.

There is an undoubted need for further research into the treatment of hepatitis C, and this review has identified several promising compounds, including Vit D, silymarin, oxymatrine, naringenin, and GTE. Some or all of these may be integral components of future HCV management.

Footnotes

P- Reviewers: De Ponti F, Julie NL, Sunbul M S- Editor: Wen LL L- Editor: A E- Editor: Liu XM

References

Source